DiaMedica Therapeutics Inc. (DMCAF) Analysts See $-0.01 EPS

November 11, 2018 - By Ellis Scott

DiaMedica Therapeutics Inc. (OTCMKTS:DMCAF) Logo

Analysts expect DiaMedica Therapeutics Inc. (OTCMKTS:DMCAF) to report $-0.01 EPS on December, 5.After having $-0.02 EPS previously, DiaMedica Therapeutics Inc.’s analysts see -50.00 % EPS growth. The stock decreased 5.28% or $0.019 during the last trading session, reaching $0.332. About 113,753 shares traded. DiaMedica Therapeutics Inc. (OTCMKTS:DMCAF) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company has market cap of $51.30 million. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It currently has negative earnings. It is also developing DM199 for the treatment vascular dementia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>